JP6587934B2 - Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用 - Google Patents

Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用 Download PDF

Info

Publication number
JP6587934B2
JP6587934B2 JP2015503617A JP2015503617A JP6587934B2 JP 6587934 B2 JP6587934 B2 JP 6587934B2 JP 2015503617 A JP2015503617 A JP 2015503617A JP 2015503617 A JP2015503617 A JP 2015503617A JP 6587934 B2 JP6587934 B2 JP 6587934B2
Authority
JP
Japan
Prior art keywords
aptamer
pdgf
vegf
binding
aptamers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015503617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517806A5 (https=
JP2015517806A (ja
Inventor
ジャービス，ターレ・シー
ローロフ，ジョン・シー
ジェリナス，エイミー・ディー
チャン，チ
ドロレ，ダニエル・ダブリュー
ウォー，シーラ・エム
ジャンジク，ネヴォイシャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of JP2015517806A publication Critical patent/JP2015517806A/ja
Publication of JP2015517806A5 publication Critical patent/JP2015517806A5/ja
Priority to JP2019006667A priority Critical patent/JP6914284B2/ja
Application granted granted Critical
Publication of JP6587934B2 publication Critical patent/JP6587934B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015503617A 2012-03-28 2013-03-28 Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用 Expired - Fee Related JP6587934B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019006667A JP6914284B2 (ja) 2012-03-28 2019-01-18 Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261616881P 2012-03-28 2012-03-28
US61/616,881 2012-03-28
US201261648394P 2012-05-17 2012-05-17
US61/648,394 2012-05-17
US201261719354P 2012-10-26 2012-10-26
US61/719,354 2012-10-26
US201261722099P 2012-11-02 2012-11-02
US61/722,099 2012-11-02
PCT/US2013/034493 WO2013149086A1 (en) 2012-03-28 2013-03-28 Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019006667A Division JP6914284B2 (ja) 2012-03-28 2019-01-18 Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用

Publications (3)

Publication Number Publication Date
JP2015517806A JP2015517806A (ja) 2015-06-25
JP2015517806A5 JP2015517806A5 (https=) 2016-02-25
JP6587934B2 true JP6587934B2 (ja) 2019-10-09

Family

ID=49261267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503617A Expired - Fee Related JP6587934B2 (ja) 2012-03-28 2013-03-28 Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
JP2019006667A Expired - Fee Related JP6914284B2 (ja) 2012-03-28 2019-01-18 Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019006667A Expired - Fee Related JP6914284B2 (ja) 2012-03-28 2019-01-18 Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用

Country Status (7)

Country Link
US (4) US9410156B2 (https=)
EP (1) EP2831278B1 (https=)
JP (2) JP6587934B2 (https=)
CN (1) CN104379764B (https=)
CA (1) CA2868096C (https=)
ES (1) ES2742284T3 (https=)
WO (1) WO2013149086A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
JP5901610B2 (ja) * 2010-04-12 2016-04-13 ソマロジック・インコーポレーテッド ５位修飾ピリミジンとその使用
JP6587934B2 (ja) 2012-03-28 2019-10-09 ソマロジック・インコーポレーテッド Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
FR2992185B1 (fr) * 2012-06-21 2015-03-27 Oreal Composition a effet matifiant comprenant des particules d'aerogels hydrophobes et des particules de silice
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
EP3044334B1 (en) * 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
JP7203613B2 (ja) * 2016-07-01 2023-01-13 ソマロジック オペレーティング カンパニー インコーポレイテッド 修飾ヌクレオシドを含むオリゴヌクレオチド
KR101833231B1 (ko) * 2016-07-14 2018-03-02 충북대학교 산학협력단 혈소판 유래 생장 인자 수용체 베타 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
CN107663220B (zh) * 2016-07-27 2020-10-02 上海伯豪医学检验所有限公司 修饰碱基、包含修饰碱基的核酸、适配体及其应用
EP3548652B1 (en) 2016-12-01 2024-04-03 Nautilus Subsidiary, Inc. Methods of assaying proteins
CN106596971A (zh) * 2016-12-16 2017-04-26 江南大学 一种基于贵金属等离子效应增强上转换荧光结构的超灵敏检测血管内皮生长因子的方法
KR20250152680A (ko) 2017-12-29 2025-10-23 노틸러스 서브시디어리, 인크. 단백질 식별을 위한 디코딩 접근법
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
CN113785062B (zh) * 2019-03-04 2025-05-16 爱普济德生物技术有限公司 适体及其用途
CN111171077A (zh) * 2020-01-19 2020-05-19 上海交通大学医学院附属仁济医院 喜树碱衍生物及其制备方法和应用
CN119552875A (zh) * 2020-03-03 2025-03-04 爱普济德生物技术有限公司 适体和其用途
WO2021252800A1 (en) 2020-06-11 2021-12-16 Nautilus Biotechnology, Inc. Methods and systems for computational decoding of biological, chemical, and physical entities
EP4281774B1 (en) 2021-01-20 2025-11-26 Nautilus Subsidiary, Inc. Biomolecule quantitation
WO2022159663A1 (en) 2021-01-21 2022-07-28 Nautilus Biotechnology, Inc. Systems and methods for biomolecule preparation
IL305336B2 (en) 2021-03-11 2025-09-01 Nautilus Subsidiary Inc Systems and methods for preserving biomolecules
CA3227872A1 (en) 2021-09-09 2023-03-16 James Henry JOLY Characterization and localization of protein modifications
AU2022352593B2 (en) 2021-09-22 2026-03-26 Nautilus Subsidiary, Inc. Methods and systems for determining polypeptide interactions
WO2023081728A1 (en) 2021-11-03 2023-05-11 Nautilus Biotechnology, Inc. Systems and methods for surface structuring
AU2022402132A1 (en) 2021-11-30 2024-05-30 Nautilus Subsidiary, Inc. Particle-based isolation of proteins and other analytes
KR20230136399A (ko) * 2022-03-18 2023-09-26 주식회사 압타머사이언스 EGFRvIII 특이적 압타머 및 이의 용도
US12092578B2 (en) 2022-03-29 2024-09-17 Nautilus Subsidiary, Inc. Integrated arrays for single-analyte processes
EP4515026A1 (en) 2022-04-25 2025-03-05 Nautilus Subsidiary, Inc. Systems and methods for assessing and improving the quality of multiplex molecular assays
US20250376716A1 (en) 2022-06-21 2025-12-11 Nautilus Subsidiary, Inc. Method for detecting analytes at sites of optically non-resolvable distances
WO2024059655A1 (en) 2022-09-15 2024-03-21 Nautilus Subsidiary, Inc. Characterizing accessibility of macromolecule structures
WO2024073599A1 (en) 2022-09-29 2024-04-04 Nautilus Subsidiary, Inc. Preparation of array surfaces for single-analyte processes
WO2024107857A1 (en) 2022-11-15 2024-05-23 Nautilus Subsidiary, Inc. Standard polypeptides
US20240192202A1 (en) 2022-12-09 2024-06-13 Nautilus Subsidiary, Inc. Fluidic media for single-analtye arrays
US20240201182A1 (en) 2022-12-15 2024-06-20 Nautilus Subsidiary, Inc. Inhibition of photon phenomena on single molecule arrays
WO2024151373A1 (en) 2023-01-12 2024-07-18 Nautilus Subsidiary, Inc. Characterization of glycans and glycoconjugates
WO2024206122A1 (en) 2023-03-24 2024-10-03 Nautilus Subsidiary, Inc. Improved transfer of nanoparticles to array surfaces
US20240353416A1 (en) 2023-04-13 2024-10-24 Nautilus Subsidiary, Inc. Artificial proteins for displaying epitopes
WO2024243237A1 (en) 2023-05-24 2024-11-28 Nautilus Subsidiary, Inc. Systems and methods for machine vision
US20250189519A1 (en) 2023-12-11 2025-06-12 Nautilus Subsidiary, Inc. Methods and compositions of particle-based arrays
US20250205706A1 (en) 2023-12-20 2025-06-26 Nautilus Subsidiary, Inc. Fluidic devices for single-analyte assays
US20250298016A1 (en) 2024-03-22 2025-09-25 Nautilus Subsidiary, Inc. Plasmonic particle systems for single-analyte assays
US20250305034A1 (en) 2024-04-01 2025-10-02 Nautilus Subsidiary, Inc. Nanostructures for modulation of analyte conformation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5599720A (en) 1982-08-27 1997-02-04 Multilyte Limited Measurement of analyte concentration
US4737453A (en) 1984-12-12 1988-04-12 Immunomedics, Inc. Sandwich immunoassay utilizing a separation specific binding substance
US4752566A (en) 1985-12-17 1988-06-21 Genetics Institute, Inc. Displacement polynucleotide method and reagent complex employing labeled probe polynucleotide
JP2635212B2 (ja) 1990-04-30 1997-07-30 アイシス・ファーマシューティカルス・インコーポレーテッド アラキドン酸代謝のオリゴヌクレオチド変調
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5849479A (en) 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6124449A (en) 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5811533A (en) 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
DK0515660T3 (da) 1990-12-21 1997-07-28 Hoffmann La Roche HLA-DQbeta-DNA-typebestemmelse
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
DE4403869C2 (de) 1994-02-08 1998-01-15 Veitsch Radex Ag Feuerfester keramischer Versatz und dessen Verwendung
WO1996027604A1 (en) 1995-03-06 1996-09-12 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
US5859228A (en) 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5723594A (en) 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
JP4531132B2 (ja) 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5945527A (en) 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6168788B1 (en) 1997-09-26 2001-01-02 Leon Wortham Fibrin glue without fibrinogen and biosealant compositions and methods
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US6312949B1 (en) 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
JP2001245671A (ja) 2000-03-07 2001-09-11 Chiba Prefecture ヒト神経芽細胞腫においてクローニングされた新規遺伝子及び新規遺伝子の断片
US6579276B2 (en) * 2001-01-22 2003-06-17 Iomed, Inc. Ocular iontophoretic device and method for inhibiting vascular endothelial growth factor (VEGF) using the same
US7831974B2 (en) 2002-11-12 2010-11-09 Intel Corporation Method and apparatus for serialized mutual exclusion
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20040180360A1 (en) 2002-11-21 2004-09-16 Charles Wilson Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
AU2004206955A1 (en) 2003-01-21 2004-08-05 Archemix Corp. Aptamer therapeutics useful in ocular pharmacotherapy
WO2004067765A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Organism fingerprinting using nicking agents
JP2007525177A (ja) * 2003-04-21 2007-09-06 アーケミックス コーポレイション 血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用
CL2004001996A1 (es) 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005052121A2 (en) * 2003-11-21 2005-06-09 Archemix Corp. Multivalent aptamers
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
AU2005206389A1 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
ATE481887T1 (de) * 2004-02-27 2010-10-15 Hauni Maschinenbau Ag Leimmengenermittlung
KR20070101226A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
EP2436391A3 (en) * 2004-11-02 2012-07-04 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2634987C (en) 2006-01-17 2017-01-03 Somalogic, Inc. Multiplexed analyses of test samples
TW200844389A (en) * 2006-12-08 2008-11-16 Sachtleben Chemie Gmbh Molded body containing titanium
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
US8569252B2 (en) * 2009-04-15 2013-10-29 Postech Academy-Industry Foundation Nucleolin specific aptamer and use thereof
DE102009031995A1 (de) 2009-07-06 2011-01-13 Neutrik Aktiengesellschaft Verfahren zur drahtlosen Echtzeitübertragung zumindest eines Audiosignales
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
JP5901610B2 (ja) 2010-04-12 2016-04-13 ソマロジック・インコーポレーテッド ５位修飾ピリミジンとその使用
WO2011130065A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ITRM20100536A1 (it) 2010-10-12 2012-04-12 Consiglio Nazionale Ricerche Aptamero inibitore di egfr per uso in terapia e diagnosi
CN103562215B (zh) * 2011-04-01 2017-04-26 埃西斯药品公司 信号转导及转录激活蛋白3(stat3)表达的调节
WO2013064702A2 (en) 2011-11-03 2013-05-10 Diagenic Asa Probes for diagnosis and monitoring of neurodegenerative disease
JP6587934B2 (ja) 2012-03-28 2019-10-09 ソマロジック・インコーポレーテッド Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
EP3044334B1 (en) 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders

Also Published As

Publication number Publication date
US20150105452A1 (en) 2015-04-16
EP2831278A1 (en) 2015-02-04
US9410156B2 (en) 2016-08-09
CA2868096A1 (en) 2013-10-03
JP6914284B2 (ja) 2021-08-04
JP2019068851A (ja) 2019-05-09
CN104379764A (zh) 2015-02-25
EP2831278A4 (en) 2015-10-28
CA2868096C (en) 2019-12-31
EP2831278B1 (en) 2019-05-08
HK1204014A1 (en) 2015-11-06
ES2742284T3 (es) 2020-02-13
US10221421B2 (en) 2019-03-05
US11208663B2 (en) 2021-12-28
US9701967B2 (en) 2017-07-11
US20160298118A1 (en) 2016-10-13
JP2015517806A (ja) 2015-06-25
US20200056181A1 (en) 2020-02-20
WO2013149086A1 (en) 2013-10-03
US20170260531A1 (en) 2017-09-14
CN104379764B (zh) 2018-04-06

Similar Documents

Publication Publication Date Title
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
JP7209025B2 (ja) 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
JP2012528597A (ja) 血小板グリコプロテインｖｉの核酸調節因子
US12534734B2 (en) Stem-loop compositions and methods for inhibiting interleukin-8
WO2020247850A1 (en) Compositions and methods for inhibiting angiopoietin-2
US12540330B2 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growth factor
HK40033269A (en) Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
HK1204014B (en) Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
BR112014024275B1 (pt) Aptâmeros para pdgf e vegf, uso dos mesmos e construto de aptâmero

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190911

R150 Certificate of patent or registration of utility model

Ref document number: 6587934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees